188 related articles for article (PubMed ID: 28196297)
1. Targeting invasive properties of melanoma cells.
Arozarena I; Wellbrock C
FEBS J; 2017 Jul; 284(14):2148-2162. PubMed ID: 28196297
[TBL] [Abstract][Full Text] [Related]
2. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.
Wessely A; Steeb T; Berking C; Heppt MV
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193
[TBL] [Abstract][Full Text] [Related]
3. In melanoma, beta-catenin is a suppressor of invasion.
Arozarena I; Bischof H; Gilby D; Belloni B; Dummer R; Wellbrock C
Oncogene; 2011 Nov; 30(45):4531-43. PubMed ID: 21577209
[TBL] [Abstract][Full Text] [Related]
4. Emerging molecular targets in melanoma invasion and metastasis.
Orgaz JL; Sanz-Moreno V
Pigment Cell Melanoma Res; 2013 Jan; 26(1):39-57. PubMed ID: 23095214
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-to-mesenchymal-like transition events in melanoma.
Pedri D; Karras P; Landeloos E; Marine JC; Rambow F
FEBS J; 2022 Mar; 289(5):1352-1368. PubMed ID: 33999497
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.
Cheli Y; Giuliano S; Fenouille N; Allegra M; Hofman V; Hofman P; Bahadoran P; Lacour JP; Tartare-Deckert S; Bertolotto C; Ballotti R
Oncogene; 2012 May; 31(19):2461-70. PubMed ID: 21996743
[TBL] [Abstract][Full Text] [Related]
7. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion.
Jenei V; Sherwood V; Howlin J; Linnskog R; Säfholm A; Axelsson L; Andersson T
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19473-8. PubMed ID: 19901340
[TBL] [Abstract][Full Text] [Related]
8. The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.
Ahn A; Chatterjee A; Eccles MR
Mol Cancer Ther; 2017 Jun; 16(6):1002-1009. PubMed ID: 28576947
[TBL] [Abstract][Full Text] [Related]
9. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.
Rathore M; Girard C; Ohanna M; Tichet M; Ben Jouira R; Garcia E; Larbret F; Gesson M; Audebert S; Lacour JP; Montaudié H; Prod'Homme V; Tartare-Deckert S; Deckert M
Oncogene; 2019 Jul; 38(30):5873-5889. PubMed ID: 31253871
[TBL] [Abstract][Full Text] [Related]
10. Neurotrophin Receptors and Perineural Invasion: Analyses in Select Lineage-Unrelated Cutaneous Malignancies With a Propensity for Perineural Invasion.
Frydenlund NF; Mahalingam M
Vitam Horm; 2017; 104():497-531. PubMed ID: 28215306
[TBL] [Abstract][Full Text] [Related]
11. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.
Javelaud D; Alexaki VI; Pierrat MJ; Hoek KS; Dennler S; Van Kempen L; Bertolotto C; Ballotti R; Saule S; Delmas V; Mauviel A
Pigment Cell Melanoma Res; 2011 Oct; 24(5):932-43. PubMed ID: 21801332
[TBL] [Abstract][Full Text] [Related]
12. Critical role of glioma-associated oncogene homolog 1 in maintaining invasive and mesenchymal-like properties of melanoma cells.
Gunarta IK; Li R; Nakazato R; Suzuki R; Boldbaatar J; Suzuki T; Yoshioka K
Cancer Sci; 2017 Aug; 108(8):1602-1611. PubMed ID: 28635133
[TBL] [Abstract][Full Text] [Related]
13. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
14. Overcoming melanoma drug resistance through metabolic targeting?
Smalley KS
Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
[No Abstract] [Full Text] [Related]
15. Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity.
Vivas-García Y; Falletta P; Liebing J; Louphrasitthiphol P; Feng Y; Chauhan J; Scott DA; Glodde N; Chocarro-Calvo A; Bonham S; Osterman AL; Fischer R; Ronai Z; García-Jiménez C; Hölzel M; Goding CR
Mol Cell; 2020 Jan; 77(1):120-137.e9. PubMed ID: 31733993
[TBL] [Abstract][Full Text] [Related]
16. A gene expression signature of invasive potential in metastatic melanoma cells.
Jeffs AR; Glover AC; Slobbe LJ; Wang L; He S; Hazlett JA; Awasthi A; Woolley AG; Marshall ES; Joseph WR; Print CG; Baguley BC; Eccles MR
PLoS One; 2009 Dec; 4(12):e8461. PubMed ID: 20041153
[TBL] [Abstract][Full Text] [Related]
17. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome.
Wardwell-Ozgo J; Dogruluk T; Gifford A; Zhang Y; Heffernan TP; van Doorn R; Creighton CJ; Chin L; Scott KL
Oncogene; 2014 Feb; 33(8):1017-26. PubMed ID: 23435427
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.
Petrachi T; Romagnani A; Albini A; Longo C; Argenziano G; Grisendi G; Dominici M; Ciarrocchi A; Dallaglio K
Oncotarget; 2017 Jan; 8(4):6914-6928. PubMed ID: 28036292
[TBL] [Abstract][Full Text] [Related]
19. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.
Villares GJ; Zigler M; Bar-Eli M
Oncotarget; 2011; 2(1-2):8-17. PubMed ID: 21378407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
